Tolera Therapeutics was granted orphan drug status by the FDA for its initial lead candidate, TOL101, for prophylaxis of acute rejection of solid organ transplantation. TOL101 is a biologic protein that is designed to safely and specifically target T cells, components of the immune system that play a key role in the rejection and failure of transplanted organs.

For more information call (877) 9-TOLERA or visit www.tolera.com.